Search

Ni-based alloy matrix submicron WS2 self-lubricant composite coatings were synthesized by Nd:YAG laser cladding in the present study. A novel high-energy ball milling method was adopted to encapsulate nano-Ni onto submicron WS2 with an aim to prevent the mass loss of WS2 during laser cladding process. Microstructure and phases of the laser-clad coatings were investigated to understand laser-cladding behaviors of two kinds of coating materials, i.e., Ni45–WS2–CaF2 and Ni60–WS2 (nano-Ni-encapsulated). The bare submicron WS2 and micron CaF2 were hardly to compose into Ni45 matrix coatings even if increasing the weight percentage of both WS2 and CaF2 from 7.5 to 17.5%. Ni-based alloy matrix submicron WS2 self-lubricant composite coatings were successfully synthesized through laser cladding of the Ni60–WS2 (nano-Ni-encapsulated) coating, since the high-energy ball milling of nano-Ni onto submicron WS2 significantly prevented the oxidization, reaction and vaporization of WS2 and improved the interfacial compatibility between WS2 and Ni60 matrix. The friction coefficient of the laser-clad Ni60–WS2 (nano-Ni-encapsulated) coating was reduced to about 0.36 in comparison with that of the laser-clad Ni45–WS2–CaF2 and Ni60 coatings (about 0.5–0.6) as well as the wear resistance of the laser-clad Ni60–WS2 (nano-Ni-encapsulated) was three times higher than that of the laser-clad Ni60 coating, respectively.

a statistically and clinically significant deterioration from BL but their EQ-5D index did not; at follow-up visit 2, their EQ-VAS and EQ-5D index scores were not statistically different from BL. Conclusions: In CheckMate 017, nivolumab patients’ health status improved from baseline during the first year of treatment, while docetaxel patients’ health status remained stable relative to baseline during their shorter time on treatment. These results show statistically and clinically significant improvements from baseline in health status for squamous advanced NSCLC patients treated with nivolumab. Conflict of interest: Ownership: N/A. Advisory Board: M. Reck has participated in advisory boards/been a consultant for Roche, Eli Lilly, Merck Sharpe & Dohme, Bristol-Myers Squibb, AstraZeneca, BoehringerIngelheim, Pfizer, and Novartis. Board of Directors: N/A. Corporatesponsored Research: N/A. Other Substantive Relationships: C. Coon, F. Taylor, and M. DeRosa are employees of Adelphi Values, which was paid by Bristol-Myers Squibb in connection with this study. J. Penrod, H. Dastani and L. Orsini are Bristol-Myers Squibb employees and stockholders. R. Gralla has been a consultant for Bristol-Myers Squibb.